IDH2 and glioblastoma: Concerning GBM and the new diffuse astrocytoma entry, IDH mutant, WHO CNS grade 4, given the partial presence of IDH in the previous revision and the well-known frequency and significance of the mutation, this change is cosmetic rather than functional and in large does not change the diagnostic approach [5].